Afficher la notice abrégée

dc.contributor.authorAlbillos García, Silvia María 
dc.contributor.authorMontero, Olimpio
dc.contributor.authorCalvo Simal, Sara 
dc.contributor.authorSolano, Berta
dc.contributor.authorTrejo Gabriel y Galán, José Mª
dc.contributor.authorCubo Delgado, Esther 
dc.date.accessioned2024-01-11T19:34:57Z
dc.date.available2024-01-11T19:34:57Z
dc.date.issued2021
dc.identifier.issn1353-8020
dc.identifier.urihttp://hdl.handle.net/10259/8307
dc.description.abstractBackground and purpose Given the overlapping clinical manifestations and pathology, the differentiation between essential tremor (ET) and Parkinson's disease (PD) is difficult. Our aims were to examine the plasma metabolomics profiling and their association with motor and non-motor symptoms (NMS) in patients with PD, and to determine differences between de novo PD compared to moderate-advanced PD vs. controls and patients with ET. Methods Plasma samples were collected from 137 subjects including 35 age matched controls, 29 NOVO-PD, 35 PD and 38 ET patients. PD severity, motor and NMS including cognitive function were assessed using the UPDRS, NMS and PD cognitive rating scales, respectively. Metabolomics analysis was performed by UPLC-ESI-QToF-MS followed by unsupervised multivariate statistics. The area under the curve of the biomarkers according to distribution of their concentrations and the diagnosis of PD (NOVO-PD, advanced PD) vs ET and healthy controls was used as a measurement of diagnostic ability. Results Several acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol (THS) presented good predictive accuracy (AUC higher than 0.8) for differentiating de novo PD and advanced PD from controls and ET, suggesting an alteration in the lipid oxidation pathway. In multivariate regression analysis, metabolite levels were not significantly associated with motor and NMS severity in PD. Conclusions Diverse acyl-carnitines, bilirubin, tyramine and some adrenal gland derived metabolites are suggested as potential biomarkers able to distinguish between PD from controls and ET.en
dc.description.sponsorshipThis work was supported by Junta de Castilla y León (BIO/BU06/14).en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherElsevieres
dc.relation.ispartofParkinsonism & Related Disorders. 2021, V. 91, p. 167-172es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectParkinson’s diseaseen
dc.subjectEssential tremoren
dc.subjectPlasma biomarkersen
dc.subjectBilirubinen
dc.subjectAcyl-carnitinesen
dc.subjectTyramineen
dc.subjectTetrahydro-21-deoxycortisolen
dc.subjectMotor skills disordersen
dc.subject.otherQuímicaes
dc.subject.otherChemistryen
dc.subject.otherBioquímicaes
dc.subject.otherBiochemistryen
dc.subject.otherBiotecnologíaes
dc.subject.otherBiotechnologyen
dc.subject.otherNeurologíaes
dc.subject.otherNeurologyen
dc.titlePlasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in Parkinson's disease and essential tremor. A case control biomarker studyen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.1016/j.parkreldis.2021.09.014es
dc.identifier.doi10.1016/j.parkreldis.2021.09.014
dc.identifier.essn1873-5126
dc.journal.titleParkinsonism & Related Disordersen
dc.volume.number91es
dc.page.initial167es
dc.page.final172es
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersiones


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée